Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases

Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases

US Patent 12121517 · Granted Oct 22, 2024

Estimated economic value: $211,575,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Combination of zibotentan and dapagliflozin for the treatment of endothelin rela2025
Combination of zibotentan and dapagliflozin for the treatment of endothelin rela2025
Combination of zibotentan and dapagliflozin for the treatment of endothelin rela2025
Combination of zibotentan and dapagliflozin for the treatment of endothelin rela2025
Combination of zibotentan and dapagliflozin for the treatment of endothelin rela2025
Combination of zibotentan and dapagliflozin for the treatment of endothelin rela2025
Combination of zibotentan and dapagliflozin for the treatment of endothelin rela2023
Combination of zibotentan and dapagliflozin for the treatment of endothelin rela2023
Combination of zibotentan and dapagliflozin for the treatment of endothelin rela2023
Combination of zibotentan and dapagliflozin for the treatment of endothelin rela2023
Combination of zibotentan and dapagliflozin for the treatment of endothelin rela2023
Combination of zibotentan and dapagliflozin for the treatment of endothelin rela2023